Steigerwald Gordon & Koch Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)

Steigerwald Gordon & Koch Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 112,428 shares of the company’s stock after buying an additional 1,331 shares during the quarter. Johnson & Johnson makes up 1.8% of Steigerwald Gordon & Koch Inc.’s investment portfolio, making the stock its 26th largest position. Steigerwald Gordon & Koch Inc.’s holdings in Johnson & Johnson were worth $16,259,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Itau Unibanco Holding S.A. boosted its position in shares of Johnson & Johnson by 7.5% in the second quarter. Itau Unibanco Holding S.A. now owns 3,018 shares of the company’s stock worth $441,000 after acquiring an additional 211 shares during the last quarter. Harmony Asset Management LLC boosted its position in shares of Johnson & Johnson by 22.2% in the second quarter. Harmony Asset Management LLC now owns 19,211 shares of the company’s stock worth $2,808,000 after acquiring an additional 3,490 shares during the last quarter. Magnetar Financial LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth approximately $80,751,000. Evergreen Capital Management LLC boosted its position in shares of Johnson & Johnson by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 110,063 shares of the company’s stock worth $16,087,000 after acquiring an additional 4,009 shares during the last quarter. Finally, Providence Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 12.4% in the second quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock worth $5,979,000 after acquiring an additional 4,500 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE:JNJ opened at $147.03 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a fifty day simple moving average of $148.51 and a 200 day simple moving average of $156.10. The firm has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on JNJ shares. Bank of America decreased their target price on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.